SAGE THERAPEUTICS INC (SAGE)

US78667J1088 - Common Stock

13.69  +0.11 (+0.81%)

After market: 13.69 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
6.3M
-99.43%		7.7M
22.22%		86.455M
1,022.79%		37.829M
-56.24%
EBITDA
YoY % growth
-456.7M
-172.90%		-545.9M
-19.53%		-545.07M
0.15%		-417.666M
23.37%		N/AN/AN/A
EBIT
YoY % growth
-460.9M
-173.87%		-547M
-18.68%		-546.463M
0.10%		-408.913M
25.17%
Operating Margin
-7,315.87%-7,103.90%-632.08%-1,080.95%
EPS
YoY % growth
-7.80
-167.01%		-8.98
-15.13%		-10.31
-14.81%		-6.37
38.26%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-1.67
37.73%
Revenue
Q2Q % growth		7.247M
189.88%
EBITDA
Q2Q % growth		-117.011M
EBIT
Q2Q % growth		-107.126M
37.17%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2024
Q2Q % growth		 -1.80
26.83%		-1.68-0.12-7.14%
Q4 2023
Q2Q % growth		 -1.80
27.13%		-1.30-0.50-38.16%
Q3 2023
Q2Q % growth		 -3.37
-45.89%		-2.79-0.58-21.00%
Q2 2023
Q2Q % growth		 -2.68
-25.82%		-2.60-0.08-2.89%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2024
Q2Q % growth		 7.902M
139.45%		5.771M2.131M36.93%
Q4 2023
Q2Q % growth		 77.972M
2,588.69%		62.197M15.775M25.36%
Q3 2023
Q2Q % growth		 2.7M
58.82%		4.71M-2.01M-42.68%
Q2 2023
Q2Q % growth		 2.5M
66.67%		3.002M-502K-16.72%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-1.95% 8.25% -0.37% -1.68%
Revenue-4.22% -38.83% -2.14% -51.9%